<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In a 2-year prospective study of 146 patients with <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo>, we compared vascular risk factors for <z:hpo ids='HP_0001297'>stroke</z:hpo> with clinical and laboratory findings, particularly <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Ten patients (6.8%) were positive for at least one <z:hpo ids='HP_0003613'>antiphospholipid antibody</z:hpo>; one patient had <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo>, one had <z:hpo ids='HP_0001370'>rheumatoid arthritis</z:hpo>, and the remaining eight fulfilled criteria for the diagnosis of <z:e sem="disease" ids="C0409980" disease_type="Disease or Syndrome" abbrv="">primary antiphospholipid syndrome</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>These patients were predominantly male, not necessarily young, and 50% of them did not have any other vascular risk factors; there were no significant clinical or paraclinical differences between these patients and those without <z:hpo ids='HP_0003613'>antiphospholipid antibodies</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Outcome in the 10 patients was good, and platelet antiaggregating drugs proved to be useful in preventing further cerebrovascular ischemic events in our patients </plain></SENT>
</text></document>